Kiniksa Pharmaceuticals Ltd (KNSA)vsUnited Therapeutics Corporation (UTHR)
KNSA
Kiniksa Pharmaceuticals Ltd
$45.84
+2.00%
HEALTHCARE · Cap: $3.44B
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 370% more annual revenue ($3.18B vs $677.56M). UTHR leads profitability with a 41.9% profit margin vs 8.7%. UTHR trades at a lower P/E of 19.4x. UTHR earns a higher WallStSmart Score of 67/100 (B-).
KNSA
Buy51
out of 100
Grade: C-
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.1%
Fair Value
$35.10
Current Price
$45.84
$10.74 premium
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Conservative balance sheet, low leverage
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 59.9x leaves little room for execution misses.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while UTHR is a mature play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.86 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 51/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?